Clinical trial
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
NCT00077922 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00077922 |
|---|---|
| Title | Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia |
| Official title | A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Chronic |
| Intervention type | Drug |
| Interventions | LMB-2 |
| Enrollment | 15 |
| Start date | Feb 29, 2004 |
| Primary completion | Dec 31, 2011 |
| Completion | Dec 31, 2011 |
| First posted | Feb 13, 2004 |
| Last update posted | Jan 23, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: